Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 100

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 100
---
ated
filer” under the rules of the SEC. For as long as we remain a “non-accelerated filer,” our independent registered public
accounting firm is not required to deliver an annual attestation report on the effectiveness of our internal control over financial reporting.
We will cease to be a non-accelerated filer if (a) the aggregate market value of our outstanding Ordinary Shares held by non-affiliates
as of the last business day of our most recently completed second fiscal quarter is $75 million or more and we reported annual net revenues
of greater than $100million for our most recently completed fiscal year or (b) the aggregate market value of our outstanding
Ordinary Shares held by non-affiliates as of the last business day of our most recently completed second fiscal quarter is $700million
or more, regardless of annual net revenues. If we cease to be a non-accelerated filer, we would be subject to the requirement
for an annual attestation report by our independent registered public accounting firm on the effectiveness of our internal control over
financial reporting. We cannot predict whether investors will find our securities less attractive if we rely on this exemption. If some
investors find our securities less attractive as a result, there may be a less active trading market for our securities and our stock
price may be more volatile and may decline.

Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.

We are subject to certain
periodic reporting requirements of the Exchange Act. We design our disclosure controls and procedures to reasonably assure that information
we are required to disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded,
processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure
controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not
absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments
in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented
by the individual acts of some persons, by collusion of two or more people, or by an unauthorized override of the controls. Accordingly,
because of the inherent limitations in our control system, misstatements or insufficient disclosure due to error or fraud may occur and
we may not detect them.

Any failure to maintain effective